Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Gets Strict On Liquid OTC Dosing Devices In Draft Guidance

This article was originally published in The Tan Sheet

Executive Summary

Some drug firms may need to alter their product packaging and labeling to comply with FDA's guidance on dosing device labeling for liquid OTCs

You may also be interested in...



Draft Pediatric Acetaminophen Guidance Drills Down With Details To Cut Overdose Risk

FDA outlines previous recommendations to reduce the risk of pediatric overdose with acetaminophen products due either to unsupervised ingestion or therapeutic errors, with greater detail on delivery devices and labeling information for pediatric acetaminophen OTCs.

Draft Pediatric Acetaminophen Guidance Drills Down With Details To Cut Overdose Risk

FDA outlines previous recommendations to reduce the risk of pediatric overdose with acetaminophen products due either to unsupervised ingestion or therapeutic errors, with greater detail on delivery devices and labeling information for pediatric acetaminophen OTCs.

Draft Guidance Drills Down With Details To Cut Pediatric Acetaminophen Overdose Risk

FDA suggests new and repeats previous recommendations to reduce the risk of pediatric overdose with acetaminophen products due either to unsupervised ingestion or therapeutic errors. The guidance includes greater detail on delivery devices and labeling information for pediatric acetaminophen OTCs.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS103500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel